Cyclosporin A-Induced Lipid and Protein Oxidation in Human B-Cells and in Epstein-Barr Virus-Infected B-Cells is Prevented by Antioxidants

REFERENCES

• Wasson S, Zafar M N, Best J, et al. Post-transplantation lymphoproliferative disorder in heart and kidney transplant patients: a single-center experience. J Cardiovasc Pharmacol Ther 2006; 11: 77–83
   PubMed Web of Science ®Google Scholar
• Penn I, Brunson M E. Cancers after cyclosporine therapy. Transplant Proc 1988; 20: 885–892
   PubMed Web of Science ®Google Scholar
• London N J, Farmery S M, Will E J, et al. Risk of neoplasia in renal transplant patients. Lancet 1995; 346: 403–406
   PubMed Web of Science ®Google Scholar
• Rickinson A, Kieff E. Epstein-Barr virus. Fields Virology, D M Knipe, P M Howley. Lippincott-Raven Publishers, Philadelphia 2001; 2575–2627
   Google Scholar
• Barth S A, Inselmann G, Engemann R, et al. Influences of Ginkgo biloba on cyclosporin A induced lipid peroxidation in human liver microsomes in comparison to vitamin E, glutathione and N-acetylcysteine. Biochem Pharmacol 1991; 41: 1521–1526
   PubMed Web of Science ®Google Scholar
• Chen C, Johnston T D, Reddy K S, et al. Cyclosporine directly causes oxidative stress and promotes Epstein-Barr virus transformation of human B cells. J Surg Res 2001; 100: 166–170
   PubMed Web of Science ®Google Scholar
• Ranjan D, Siquijor A, Johnston T D, et al. The effect of curcumin on human B-cell immortalization by Epstein-Barr virus. Am Surg 1998; 64: 47–51
   PubMed Web of Science ®Google Scholar
• Anjaneyulu M, Tirkey N, Chopra K. Attenuation of cyclosporine-induced renal dysfunction by catechin: possible antioxidant mechanism. Ren Fail 2003; 25: 691–707
   PubMed Web of Science ®Google Scholar
• Hagar H H. The protective effect of taurine against cyclosporine A-induced oxidative stress and hepatotoxicity in rats. Toxicol Lett 2004; 51: 335–343
   Google Scholar
• Esterbauer H, Cheeseman K H. Determination of aldehydic lipid peroxidation products: malonaldehyde and 4-hydroxynonenal. Methods Enzymol 1990; 186: 407–421
   PubMed Web of Science ®Google Scholar
• Aksenov M Y, Aksenova M V, Butterfield D A, et al. Protein oxidation in the brain in Alzheimer's disease. Neuroscience 2001; 103: 373–383
   PubMed Web of Science ®Google Scholar
• Fimognari C, Nusse M, Cesari R, et al. Growth inhibition, cell-cycle arrest and apoptosis in human T-cell leukemia by the isothiocyanate sulforaphane. Carcinogenesis 2002; 23: 581–586
   PubMed Web of Science ®Google Scholar
• Suthanthiran M, Strom T B. Renal transplantation. N Engl J Med 1994; 331: 365–376
   PubMed Web of Science ®Google Scholar
• Serino F, Grevel J, Napoli K L, et al. Generation of oxygen free radicals during the metabolism of cyclosporine A: a cause–effect relationship with metabolism inhibition. Mol Cell Biochem 1993; 122: 101–112
   PubMed Web of Science ®Google Scholar
• Ahmed S S, Strobel H W, Napoli K L, et al. Adrenochrome reaction implicates oxygen radicals in metabolism of cyclosporine A and FK-506 in rat and human liver microsomes. J Pharmacol Exp Ther 1993; 265: 1047–1054
   PubMed Web of Science ®Google Scholar
• Nguyen N S, Cottet-Maire F, Buetler T M, et al. Metabolism-dependent stimulation of reactive oxygen species and DNA synthesis by cyclosporin A in rat smooth muscle cells. Free Radic Biol Med 1999; 27: 1267–1275
   PubMed Web of Science ®Google Scholar
• Parra T, de Arriba G, Conejo J R, et al. Cyclosporine increases local glomerular synthesis of reactive oxygen species in rats: effect of vitamin E on cyclosporine nephrotoxicity. Transplantation 1998; 66: 1325–1329
   PubMed Web of Science ®Google Scholar
• Durak I, Kacmaz M, Cimen M Y, et al. The effects of cyclosporine on antioxidant enzyme activities and malondialdehyde levels in rabbit hepatic tissues. Transpl Immunol 2002; 10: 255–258
   PubMed Web of Science ®Google Scholar
• Duthie S J, Melvin W T, Burke M D. Drug toxicity mechanisms in human hepatoma HepG2 cells: cyclosporin A and tamoxifen. Xenobiotica 1995; 25: 1151–1164
   PubMed Web of Science ®Google Scholar
• Walker R J, Lazzaro V A, Duggin G G, et al. Evidence that alterations in renal metabolism and lipid peroxidation may contribute to cyclosporine nephrotoxicity. Transplantation 1990; 50: 487–492
   PubMed Web of Science ®Google Scholar
• Ranjan D, Chen C, Johnston T D, et al. Stimulation of Epstein-Barr virus-infected human B cell growth by physiological concentrations of 4-hydroxynonenal. Cell Biochem Funct 2006; 24: 147–152
   PubMed Web of Science ®Google Scholar
• Tanaka H, Nakahata T, Ito E. Single-dose daily administration of cyclosporin A for relapsing nephrotic syndrome. Pediatr Nephrol 2004; 19: 1055–1058
   PubMed Web of Science ®Google Scholar
• Masri M A, Haberal M, Rizvi A, et al. The pharmacokinetics of equoral versus neoral in stable renal transplant patients: a multinational multicenter study. Transplant Proc 2004; 36: 80–83
   PubMed Web of Science ®Google Scholar
• Oshima K, Kanda Y, Nakasone H, et al. Decreased incidence of acute graft-versus-host disease by continuous infusion of cyclosporine with a higher target blood level. Am J Hematol 2008; 83: 226–232
   PubMed Web of Science ®Google Scholar
• Chen C, Reddy K S, Johnston T D, et al. Vitamin E inhibits cyclosporin A and H2O2 promoted Epstein-Barr virus (EBV) transformation of human B cells as assayed by EBV oncogene LMP1 expression. J Surg Res 2003; 113: 228–233
   PubMed Web of Science ®Google Scholar